Home Capital Broker's Calls

DBS reinstates coverage on CICT with “buy”, TP of $2.50

Atiqah Mokhtar
Atiqah Mokhtar12/10/2021 04:09 PM GMT+08  • 2 min read
DBS reinstates coverage on CICT with “buy”, TP of $2.50
DBS sees CICT as a key proxy and beneficiary of the reopening play.
Font Resizer
Share to WhatsappShare to FacebookShare to LinkedInMore Share
Scroll to top
Follow us on Facebook and join our Telegram channel for the latest updates.

DBS Group Research has reinstated coverage on CapitaLand Integrated Commercial Trust with a “buy” call and target price of $2.50.

In a Dec 10 research note, analysts Rachel Tan and Derek Tan state that CICT is a key proxy and beneficiary of the reopening play. “We estimate CICT could deliver c.12% of DPU growth in FY2022 and a 9% two-year compound annual growth rate, one of the stronger growth rates among peers,” they say.

Despite concerns surrounding the Omicron variant dampening reopening optimism, the analysts believe that quicker recovery is around the corner, underpinned by faster response from pharmaceutical companies and higher levels of vaccination rates.

For more insights on corporate trends...
Sign In or Create an account to access our premium content.
Subscription Entitlements:
Less than $9 per month
Unlimited access to latest and premium articles
3 Simultaneous logins across all devices
Bonus unlimited access to online articles and virtual newspaper on The Edge Malaysia (single login)
Loading next article...
The Edge Singapore
Download The Edge Singapore App
Google playApple store play
Keep updated
Follow our social media
Subscribe to The Edge Singapore
Get credible investing ideas from our in-depth stock analysis, interviews with key executives, corporate movements coverage and their impact on the market.
© 2022 The Edge Publishing Pte Ltd. All rights reserved.
Unlock unlimited access to premium articles with less than $9 per month. Subscribe Now